Home / Explore Insights / Effective Clinical Trial Management and Regulatory Expertise Leads to FDA Approval of Unique Product for ADHD
/ Insights / Explore Insights / Effective Clinical Trial Management And Regulatory Expertise Leads To Fda Approval Of Unique Product For Adhd
Effective Clinical Trial Management and Regulatory Expertise Leads to FDA Approval of Unique Product for ADHD
Situation: Full-service management of two Phase 3 ADHD studies + NDA Submission = FDA Approval
The Success:
- Initially contracted for End of Phase 2 meeting support due to ADHD expertise, which led to full service management of both Phase 3 studies and subsequent NDA authorship and submission.
- Study # 1: Laboratory Classroom Study leveraged existing relationships with Rho’s go-to network of experienced classroom sites and training consultants.
- Study # 2: Examined a novel endpoint to address unmet need/gap in typical coverage period for existing ADHD medications.
- Seamless team integration between clinical monitoring, data management, and biostatistics to identify early data trends leading to training reinforcement needs for new endpoint scales.
- Produced topline results within 24 hours of database lock.
- Parallel development of clinical study reports (CSRs) and Safety/Efficacy modules to support efficient NDA submission and successful label negotiation with FDA.
Rho and the sponsor jointly navigated a new pathway from initial End of Phase 2 planning to Phase 3 trial execution to delivery of quality data to support FDA approval.